Tariff-Proof But Not China-Proof: The Geopolitics of India’s Pharma Power
AI Summary
India's pharmaceutical sector has managed to dodge new U.S. drug tariffs, thanks to Washington's decision to exempt India’s generics. However, the sector's reliance on Chinese raw materials poses a significant risk, as China controls a crucial part of the supply chain. This dependency not only threatens India's pharmaceutical industry but also impacts Western countries that rely on these drugs, highlighting a geopolitical vulnerability that could reshape global drug manufacturing strategies.
Original Source
Read the full article at Thediplomat →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.